c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma

OBJECTIVES: In the TOURMALINE‐MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib‐lenalidomide‐dexamethasone (IRd) showed different magnitudes of progression‐free survival (PFS) benefit vs placebo‐Rd according to number and type of prior therapies, with greater benefit seen in patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Haematol
Main Authors: Di Bacco, Alessandra, Bahlis, Nizar J., Munshi, Nikhil C., Avet‐Loiseau, Hervé, Masszi, Tamás, Viterbo, Luísa, Pour, Ludek, Ganly, Peter, Cavo, Michele, Langer, Christian, Kumar, Shaji K., Rajkumar, S. Vincent, Keats, Jonathan J., Berg, Deborah, Lin, Jianchang, Li, Bin, Badola, Sunita, Shen, Lei, Zhang, Jacob, Esseltine, Dixie‐Lee, Luptakova, Katarina, van de Velde, Helgi, Richardson, Paul G., Moreau, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317705/
https://ncbi.nlm.nih.gov/pubmed/32145111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13405
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados